For research use only. Not for therapeutic Use.
AZD1283 (CAT: I005479) is a chemical compound that acts as a potent antagonist of the P2Y12 receptor. The P2Y12 receptor is a member of the purinergic receptor family and is primarily expressed on platelets. By antagonizing the P2Y12 receptor, AZD1283 inhibits platelet activation and aggregation, thus affecting the clotting process. This mechanism of action makes AZD1283 a promising candidate for use in the prevention and treatment of thrombotic disorders, such as arterial thrombosis and acute coronary syndromes.
| Catalog Number | I005479 |
| CAS Number | 919351-41-0 |
| Synonyms | AZD-1283 |
| Molecular Formula | C23H26N4O5S |
| Purity | ≥95% |
| Target | P2Y Receptor |
| Solubility | 10 mM in DMSO |
| Storage | Store at -20°C |
| IC50 | 3.0 ug/kg/min(EC50) |
| IUPAC Name | ethyl 6-[4-(benzylsulfonylcarbamoyl)piperidin-1-yl]-5-cyano-2-methylpyridine-3-carboxylate |
| InChI | InChI=1S/C23H26N4O5S/c1-3-32-23(29)20-13-19(14-24)21(25-16(20)2)27-11-9-18(10-12-27)22(28)26-33(30,31)15-17-7-5-4-6-8-17/h4-8,13,18H,3,9-12,15H2,1-2H3,(H,26,28) |
| InChIKey | NEMHKCNXXRQYRF-UHFFFAOYSA-N |
| SMILES | CCOC(=O)C1=C(N=C(C(=C1)C#N)N2CCC(CC2)C(=O)NS(=O)(=O)CC3=CC=CC=C3)C |
| Reference | 1:J Med Chem. 2013 Sep 12;56(17):7015-24. doi: 10.1021/jm400820m. Epub 2013 Aug 29. Lead optimization of ethyl 6-aminonicotinate acyl sulfonamides as antagonists of the P2Y12 receptor. separation of the antithrombotic effect and bleeding for candidate drug AZD1283.Bach P,Antonsson T,Bylund R,Björkman JA,Österlund K,Giordanetto F,van Giezen JJ,Andersen SM,Zachrisson H,Zetterberg F, PMID: 23899349 DOI: 10.1021/jm400820m </br><span>Abstract:</span> Synthesis and structure-activity relationships of ethyl 6-aminonicotinate acyl sulfonamides, which are potent antagonists of the P2Y12 receptor, are presented. Shifting from 5-chlorothienyl to benzyl sulfonamides significantly increased the potency in the residual platelet count assay. Evaluation of PK parameters in vivo in dog for six compounds showed a 10-fold higher clearance for the azetidines than for the matched-pair piperidines. In a modified Folts model in dog, both piperidine 3 and azetidine 13 dose-dependently induced increases in blood flow and inhibition of ADP-induced platelet aggregation with antithrombotic ED50 values of 3.0 and 10 μg/kg/min, respectively. The doses that induced a larger than 3-fold increase in bleeding time were 33 and 100 μg/kg/min for 3 and 13, respectively. Thus, the therapeutic index (TI) was ≥ 10 for both compounds. On the basis of these data, compound 3 was progressed into human clinical trials as candidate drug AZD1283. |
